Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Boyer

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Journal of Pain Research|February 6, 2020
Safety, Tolerability, and Effect on Opioid Use of Meloxicam IV Following Orthopedic SurgeryKipling P Sharpe, Richard Berkowitz, William A Tyndall, et al.
Ocular Immunology and Inflammation|May 20, 2021
Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
The British Journal of Ophthalmology|May 20, 2014
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in cultureDeepika Malik, Mohamed Tarek, Javier Caceres del Carpio, et al.
Eye (London, England)|February 3, 2021
Brolucizumab-foreseeable workflow in the current scenarioAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|March 2, 2026
Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety studyAshish Sharma, Arshad M Khanani, David Eichenbaum, et al.
International Journal of Retina and Vitreous|August 28, 2019
Vascularized drusen: a cross-sectional studyChris Or, Jeffrey S Heier, David Boyer, et al.
Chemical Science|September 12, 2022
The rippled β-sheet layer configuration-a novel supramolecular architecture based on predictions by Pauling and CoreyAmaruka Hazari, Michael R Sawaya, Niko Vlahakis, et al.
Ophthalmology|August 25, 2009
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) studyQuan Dong Nguyen, Syed Mahmood Shah, Jeffery S Heier, et al.
Pharmaceutical Research|June 25, 2025
First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated DiseasesVenkat R Gadhachanda, Jason A Wiles, Steven D Podos, et al.
Pharmaceutical Research|July 14, 2025
Correction: First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated DiseasesVenkat R Gadhachanda, Jason A Wiles, Steven D Podos, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Journal of Pain Research|February 6, 2020
Safety, Tolerability, and Effect on Opioid Use of Meloxicam IV Following Orthopedic SurgeryKipling P Sharpe, Richard Berkowitz, William A Tyndall, et al.
Ocular Immunology and Inflammation|May 20, 2021
Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
The British Journal of Ophthalmology|May 20, 2014
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in cultureDeepika Malik, Mohamed Tarek, Javier Caceres del Carpio, et al.
Eye (London, England)|February 3, 2021
Brolucizumab-foreseeable workflow in the current scenarioAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|March 2, 2026
Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety studyAshish Sharma, Arshad M Khanani, David Eichenbaum, et al.
International Journal of Retina and Vitreous|August 28, 2019
Vascularized drusen: a cross-sectional studyChris Or, Jeffrey S Heier, David Boyer, et al.
Chemical Science|September 12, 2022
The rippled β-sheet layer configuration-a novel supramolecular architecture based on predictions by Pauling and CoreyAmaruka Hazari, Michael R Sawaya, Niko Vlahakis, et al.
Ophthalmology|August 25, 2009
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) studyQuan Dong Nguyen, Syed Mahmood Shah, Jeffery S Heier, et al.
Pharmaceutical Research|June 25, 2025
First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated DiseasesVenkat R Gadhachanda, Jason A Wiles, Steven D Podos, et al.
Pharmaceutical Research|July 14, 2025
Correction: First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated DiseasesVenkat R Gadhachanda, Jason A Wiles, Steven D Podos, et al.
Pageof 8